GamaMabs Pharma Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 9

GamaMabs Pharma General Information

Description

Developer of optimized therapeutic antibodies designed for the treatment of cancer. The company develops monoclonal antibodies with enhanced tumor cell-killing properties that target anti-Mullerian human receptors in ovarian cancer, enabling physicians to treat previously unaddressed targets in gynecological cancers.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Centre Pierre Potier, Oncopole entrée B
  • 1 place Pierre Potier BP50624
  • 31106 Toulouse
  • France
+33 01
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Corporate Office
  • Centre Pierre Potier, Oncopole entrée B
  • 1 place Pierre Potier BP50624
  • 31106 Toulouse
  • France
+33 01

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GamaMabs Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Secondary Transaction - Private 26-Mar-2026 Completed Startup
7. Later Stage VC 13-Sep-2021 Completed Startup
6. Later Stage VC 16-Jul-2020 Completed Startup
5. Later Stage VC 20-Jun-2018 Completed Startup
4. Early Stage VC (Series B) 15-Dec-2015 Completed Startup
3. Early Stage VC 03-Mar-2014 Completed Startup
2. Early Stage VC (Series A) 30-Sep-2013 $4.81M $4.81M Completed Startup
1. Accelerator/Incubator Completed Startup
To view GamaMabs Pharma’s complete valuation and funding history, request access »

GamaMabs Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Shares C
Shares B
Shares P 38,402 $2.357795 $110.52 $110.52 1x $110.52 13.35%
To view GamaMabs Pharma’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

GamaMabs Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of optimized therapeutic antibodies designed for the treatment of cancer. The company develops monoclonal anti
Drug Discovery
Toulouse, France
7 As of 2021

Cerdanyola, Spain
 

Bengaluru, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

GamaMabs Pharma Competitors (20)

One of GamaMabs Pharma’s 20 competitors is Ability Pharma, a Private Equity-Backed company based in Cerdanyola, Spain.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ability Pharma Private Equity-Backed Cerdanyola, Spain
Biocon Biologics Formerly PE-Backed Bengaluru, India
Gilead Formerly VC-backed Foster City, CA
Genentech Formerly VC-backed South San Francisco, CA
Ona Therapeutics Venture Capital-Backed Barcelona, Spain
You’re viewing 5 of 20 competitors. Get the full list »

GamaMabs Pharma Patents

GamaMabs Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025248097-A2 Humanized anti-human her3 antibodies and uses thereof Pending 31-May-2024
WO-2025248097-A3 Humanized anti-human her3 antibodies and uses thereof Pending 31-May-2024
EP-3812008-A1 Amh-competitive antagonist antibody Inactive 23-Oct-2019
US-20230348607-A1 Amh-competitive antagonist antibody Inactive 23-Oct-2019
WO-2021078959-A1 Amh-competitive antagonist antibody Inactive 23-Oct-2019 C07K16/2869
To view GamaMabs Pharma’s complete patent history, request access »

GamaMabs Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GamaMabs Pharma Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Edmond de Rothschild Private Equity PE/Buyout Minority
Andera Partners PE/Buyout Minority
IRDI Capital Investissement PE/Buyout Minority
Alto Invest Asset Manager Minority
Bpifrance Sovereign Wealth Fund Minority
You’re viewing 5 of 9 investors. Get the full list »

GamaMabs Pharma FAQs

  • When was GamaMabs Pharma founded?

    GamaMabs Pharma was founded in 2013.

  • Where is GamaMabs Pharma headquartered?

    GamaMabs Pharma is headquartered in Toulouse, France.

  • What is the size of GamaMabs Pharma?

    GamaMabs Pharma has 7 total employees.

  • What industry is GamaMabs Pharma in?

    GamaMabs Pharma’s primary industry is Drug Discovery.

  • Is GamaMabs Pharma a private or public company?

    GamaMabs Pharma is a Private company.

  • What is GamaMabs Pharma’s current revenue?

    The current revenue for GamaMabs Pharma is .

  • How much funding has GamaMabs Pharma raised over time?

    GamaMabs Pharma has raised $31.5M.

  • Who are GamaMabs Pharma’s investors?

    Edmond de Rothschild Private Equity, Andera Partners, IRDI Capital Investissement, Alto Invest, and Bpifrance are 5 of 9 investors who have invested in GamaMabs Pharma.

  • Who are GamaMabs Pharma’s competitors?

    Ability Pharma, Biocon Biologics, Gilead, Genentech, and Ona Therapeutics are some of the 20 competitors of GamaMabs Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process